Iradimed Corp. (IRMD) Tops Q2 EPS by 1c ; Offers Guidance

Iradimed Corp. (NASDAQ: IRMD) reported Q2 EPS of $0.46, $0.01 better than the analyst estimate of $0.45. Revenue for the quarter came in at $20.5 million versus the consensus estimate of $20.56 million.

Outlook:-

Q3 2026 revenue between $23.0 million to $24.5 million vs consensus $91.2 million.
Q3 2026 EPS between $0.54 to $0.59 vs consensus $2.09.
FY 2026 revenue between $91.0 million to $96.0 million vs consensus $25.2 million.
FY 2026 EPS between $2.09 to $2.24 vs consensus $0.61.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Simply Solventless files Q2 2026 financials amid restructuring process
• Citi Downgrades Pearson PLC (PSON:LN) (PSO) to Neutral